News

Pharmaceutical companies are rushing to develop peptide-based drugs following the blockbuster success of GLP-1 therapies for metabolic conditions.

Peptide injections moved into mainstream wellness in 2025, changing consumer attitudes toward self-administered treatments.

Sermorelin.com introduces peptide therapy program targeting patients on GLP-1 medications for optimized metabolic health outcomes.

Aesthetic neurotoxin market set for major growth through 2034, driven by demand for minimally invasive procedures and expanding applications.

Structure Therapeutics reports promising trial data for its oral GLP-1 pill, offering a potential alternative to injectable obesity drugs.

New antimicrobial peptide shows promise against bacterial pneumonia while potentially reducing antibiotic resistance development.

New research suggests hormone replacement therapy may support weight loss and bone density during menopause beyond symptom relief.

Boston’s mayor clashes with city unions as insurance costs surge for popular GLP-1 weight loss medications.

FDA removes decades-old warning labels from HRT medications, potentially transforming menopause treatment for millions of women.

New guidance clarifies HRT cancer risks, showing timing and duration critically affect safety for menopausal women.